Tycel J. Phillips, MD

Articles

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL

January 12th 2024

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr Phillips on Treatment With Bispecific Antibodies and CAR T-Cell Therapy in MCL

September 19th 2023

Tycel Phillips, MD, MPH, discusses treatment with bispecific antibodies and CAR T-cell therapy in patients with mantle cell lymphoma, and other non-Hodgkin lymphomas.

Dr. Phillips on BTK Inhibitor Selection in MCL

March 15th 2023

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

June 30th 2022

Dr. Tycel Phillips reviews pivotal dose-expansion results from the EPCORE NHL-1 trial on epcoritamab in patients with relapsed or refractory large B-cell lymphoma (LBCL).

Rapid Readout: Phase 1/2 Trial of Subcutaneous Epcoritamab With R-Squared in Patients with Relapsed or Refractory Follicular Lymphoma

February 8th 2022

Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

Dr. Phillips Discusses Ongoing Research With BTK Inhibitors in MCL

January 19th 2022

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Dr. Phillips Discusses Ongoing Trials in MCL

January 17th 2022

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

January 3rd 2022

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Dr. Phillips on the Next Steps With Venetoclax/Lenalidomide/Rituximab in MCL

July 7th 2021

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Philips on the Design of a Phase 1 Trial With Venetoclax/Lenalidomide/Rituximab in MCL

June 21st 2021

Tycel Jovelle Phillips, MD, discusses the design of a phase 1 trial with venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Phillips on the Toxicity Profile of Venetoclax/Lenalidomide/Rituximab in MCL

June 11th 2021

Tycel Jovelle Phillips, MD, discusses the toxicity profile of the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Phillips Discusses Novel Treatment Regimen in MCL

January 23rd 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses a novel treatment regimen for patients with mantle cell lymphoma.

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

January 11th 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

Dr. Phillips on Emerging Combination in MCL

December 20th 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses an emerging combination in the treatment of patients with mantle cell lymphoma.

Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL

December 2nd 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.